Reaction Details |
| Report a problem with these data |
Target | Mitogen-activated protein kinase 8 |
---|
Ligand | BDBM50192071 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_404535 (CHEMBL910918) |
---|
IC50 | >1000±n/a nM |
---|
Citation | Kawanishi, N; Sugimoto, T; Shibata, J; Nakamura, K; Masutani, K; Ikuta, M; Hirai, H Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorg Med Chem Lett16:5122-6 (2006) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Mitogen-activated protein kinase 8 |
---|
Name: | Mitogen-activated protein kinase 8 |
Synonyms: | JNK-46 | JNK1 | JNK1-alpha-1 | MAPK8 | MK08_HUMAN | Mitogen-Activated Protein Kinase 8 (JNK1) | PRKM8 | SAPK1 | SAPK1C | Stress-activated protein kinase JNK1 | c-Jun N-terminal kinase 1 | c-Jun N-terminal kinase 1 (JNK1) | c-Jun N-terminal kinase 1(JNK1) | c-Jun N-terminal kinase 2 (JNK2) |
Type: | Enzyme |
Mol. Mass.: | 48297.57 |
Organism: | Homo sapiens (Human) |
Description: | JNK-1 was purchased from Upstate Cell Signaling Solutions (formerly Upstate Biotechnology). |
Residue: | 427 |
Sequence: | MSRSKRDNNFYSVEIGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRP
FQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQ
MELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSF
MMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCHKILFPGRDYIDQWNKVIEQ
LGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSK
MLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEV
MDLEERTKNGVIRGQPSPLGAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAA
GPLGCCR
|
|
|
BDBM50192071 |
---|
n/a |
---|
Name | BDBM50192071 |
Synonyms: | (13R,15S)-13-methyl-16-oxa-8,9,12,22,24-pentaazahexacyclo[15.6.2.1^{6,9}.1^{12,15}.0^{2,7}.0^{21,25}]heptacosa-1(24),2,4,6(27),7,17(25),18,20,22-nonaene-23,27-diol | CHEMBL215803 |
Type | Small organic molecule |
Emp. Form. | C22H21N5O3 |
Mol. Mass. | 403.4338 |
SMILES | C[C@@H]1C[C@H]2CN1CCn1[nH]c3c(cccc3c1=O)-c1nc3c(O2)cccc3[nH]c1=O |
Structure |
|